Note 9 - Related Party Transactions	9 Months Ended
Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date. On May 1, 2019, Mr. Gabriel executed a one -year contract with renewable three -month periods to continue as Chief Operating Officer for TumorGenesis. Mr. Gabriel will receive $13,500 in monthly cash payments. On May 21, 2019, the Company issued a third and restated common stock purchase warrant to Dr. Carl Schwartz, the Company’s CEO, for value received in connection with the funding of all or a portion of the purchase price of his second amended and restated promissory note in the principal amount of $1,620,000. The Company has accounted for the liability to issue more warrants as a derivative liability as the exact number of warrants that will be issued was uncertain at the time of the agreement. The Company issued an additional 3,451 warrants to Dr. Schwartz under the agreement in the third quarter, which reduced the value of the derivative liability by $14,863. As of September 30, 2019, the recorded derivative liability related to the agreement was $22,644. During 2019, Dr. Schwartz advanced $300,000 to the Company. The loan earns 8% interest per annum. The due date of the loan was amended and the loan is now due December 31, 2019. No additional consideration was given for this extension. The loan is not connected to the previous note payable due to Dr. Schwartz.

NOTE

– RELATED PARTY TRANSACTIONS

The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company

may

be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements.

One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been

revenue or expenses generated by this partnership to date.

May 1, 2019,

Mr. Gabriel executed a

one

-year contract with renewable

three

-month periods to continue as Chief Operating Officer for TumorGenesis. Mr. Gabriel will receive

$13,500

in monthly cash payments.

May 21, 2019,

the Company issued a

third

and restated common stock purchase warrant to Dr. Carl Schwartz, the Company’s CEO, for value received in connection with the funding of all or a portion of the purchase price of his

second

amended and restated promissory note in the principal amount of

$1,620,000.

The Company has accounted for the liability to issue more warrants as a derivative liability as the exact number of warrants that will be issued was uncertain at the time of the agreement. The Company issued an additional

3,451

warrants to Dr. Schwartz under the agreement in the

third

quarter, which reduced the value of the derivative liability by

$14,863.

As of

September 30, 2019,

the recorded derivative liability related to the agreement was

$22,644.

During

2019,

Dr. Schwartz advanced

$300,000

to the Company. The loan earns

interest per annum. The due date of the loan was amended and the loan is now due

December 31, 2019.

additional consideration was given for this extension. The loan is

not

connected to the previous note payable due to Dr. Schwartz.